CD8A and neoplasm: In the TOPACIO study, which evaluated the combination of niraparib and pembrolizumab in patients with ovarian carcinoma, single-cell analyses concluded that HRD status (as assessed by the “Sig3” specific mutational signature that also takes into account large deletions), CD8-exhausted effector T-cells in the tumour microenvironment and activation of the interferon pathway could be used as surrogate biomarkers of response [218].